Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab | Zendy

Stephen D. Smith | Zendy; Javier Muñoz | Zendy; Don A. Stevens | Zendy; Sonali M. Smith | Zendy; Tatyana Feldman | Zendy; J Christine Ye | Zendy; Sven de Vos | Zendy; Brian T. Hess | Zendy; Carole B. Miller | Zendy; James Khatcheressian | Zendy; Matt Birrell | Zendy; Janet M. Leeds | Zendy; Gregory P. Coffey | Zendy; Pamela B. Conley | Zendy; Glenn Michelson | Zendy; John T. Curnutte | Zendy; Paul A. Hamlin | Zendy

Open Access

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Author(s) -

Stephen D. Smith,

Javier Muñoz,

Don A. Stevens,

Sonali M. Smith,

Tatyana Feldman,

J Christine Ye,

Sven de Vos,

Brian T. Hess,

Carole B. Miller,

James Khatcheressian,

Matt Birrell,

Janet M. Leeds,

Gregory P. Coffey,

Pamela B. Conley,

Glenn Michelson,

John T. Curnutte,

Paul A. Hamlin

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood-2019-124231

Subject(s) - idelalisib , follicular lymphoma , medicine , chemoimmunotherapy , syk , rituximab , oncology , lymphoma , follicular phase , cancer research , ibrutinib , pharmacology , immunology , leukemia , chronic lymphocytic leukemia , tyrosine kinase , receptor

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research